Table 1 Sample size and basic demographic and genomic control inflation factor.

Study	Group	Total	Gender		Age	Platform						Genomic control inflation factor
Study	Group	Total	M	F	(0,30)	(30,45)	(45,60)	z	v1/v2	v3	v4	λ	λ₁₀₀₀	λ₁₀₀₀₀
AES	SSRI responders vs. non-responders
	Responders	8491	2048	6443	993	2103	2511	2884	49	638	7804
	Non-responders	4046	1117	2929	728	1189	1171	958	18	312	3716	1.015	1.003	1.027
AES	SNRI responders vs. non-responders
	Responders	2055	451	1604	111	443	747	754	5	176	1874
	Non-responders	1950	504	1446	195	544	664	547	5	172	1773	1.017	1.008	1.083
AES	NDRI responders vs. non-responders
	Responders	1616	502	1114	148	455	567	446	10	124	1482
	Non-responders	2068	602	1466	280	621	679	488	9	183	1876	1.01	1.006	1.058
AES	NTRD vs. TRD
	NTRD	17214	4281	12933	1733	4182	5501	5798	95	1323	15796
	TRD	3168	894	2274	493	893	1002	780	14	265	2889	1.016	1.003	1.031
AESES	SNRI responders vs. non-responders
	Responders	2547	656	1891	160	614	833	940	37	761	1749	1.013	1.007	1.07
	Non-responders	1567	508	1059	159	491	510	407	18	517	1032
AESES	NDRI responders vs. non-responders
	Responders	2675	799	1876	297	710	914	754	46	840	1789
	Non-responders	1861	656	1205	300	569	541	451	27	663	1171	1.007	1.003	1.032
AESES	SSRI responders vs. non-responders
	Responders	6348	1770	4578	671	1543	2033	2101	103	1997	4248
	Non-responders	3340	1229	2111	666	1106	863	705	44	1128	2168	1.008	1.002	1.018
AESES	NTRD vs. TRD
	Responders	7795	2204	5591	799	1834	2547	2615	122	2321	5352
	Non-responders	1311	517	794	271	420	349	271	14	445	852	1.019	1.009	1.086

AES Antidepressant Efficacy Survey, AESES Antidepressant Efficacy and Side Effects Survey, NDRI norepinephrine–dopamine reuptake inhibitor, NTRD non-treatment-resistant depression, SNRI serotonin-norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TRD treatment-resistant depression. Note that analyses reported previously in Li et al., 2016 have been italicized.

Search